Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Wilms Tumor Protein (WT33 or WT1) - Overview
Wilms Tumor Protein (WT33 or WT1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Wilms Tumor Protein (WT33 or WT1) - Therapeutics Assessment
Assessment by Route of Administration
Assessment by Molecule Type
Wilms Tumor Protein (WT33 or WT1) - Companies Involved in Therapeutics Development
Cue Biopharma Inc
Inovio Pharmaceuticals Inc
Scancell Holdings Plc
SELLAS Life Sciences Group Inc
Sumitomo Dainippon Pharma Co Ltd
tella Inc
Vaximm AG
Wilms Tumor Protein (WT33 or WT1) - Drug Profiles
Cellular Immunotherapy to Target WT1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CUE-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
galinpepimut-S - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INO-5401 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ombipepimut-s - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TLP-0001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target NY-ESO-1, PRAME, MAGE-A3 and WT-1 for Acute Myeloid Leukemia and Myelodysplastic Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target Wilm’s Tumor 1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target Wilms Tumor Protein for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target WT1 for Glioblastoma Multiforme - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target WT1 for Leukemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target WT1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target WT1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target WT1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VXM-06 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Wilms Tumor Protein (WT33 or WT1) - Dormant Products
Wilms Tumor Protein (WT33 or WT1) - Discontinued Products
Wilms Tumor Protein (WT33 or WT1) - Product Development Milestones
Featured News & Press Releases
Nov 08, 2019: Boston Biomedical highlights phase 1 data evaluating investigatiol WT1 Cancer Peptide Vaccine DSP-7888 (ombipepimut-S) in patients with advanced maligncies at SITC 2019
Nov 08, 2019: SELLAS to host R&D investor event on Galinpepimut-S (GPS) and the next generation of cancer immunotherapy
Nov 05, 2019: Inovio demonstrates 80% 6-month progression-free survival in phase 2 Glioblastoma Multiforme (GBM) study with INO-5401 in combition with PD-1 inhibitor Libtayo (cemiplimab)
Jul 31, 2019: SELLAS advances Galinpepimut-S (GPS) in combition with KEYTRUDA (pembrolizumab) program with dosing of first patient in phase 1/2 basket study
Apr 04, 2019: SELLAS Life Sciences Group and World-Renowned Cancer Center to Study Galinpepimut-S (GPS) in Combition with Nivolumab in Patients with Malignt Pleural Mesothelioma (MPM)
Apr 03, 2019: Inovio closes enrolment in Phase I/II glioblastoma trial
Feb 12, 2019: SELLAS Life Sciences provides Galinpepimut-S program update
Jan 29, 2019: John Theurer Cancer Center leading enrollment for global phase 2 WIZARD study evaluating DSP-7888 in patients with recurrent glioblastoma
Jan 08, 2019: SELLAS Life Sciences provides update on Galinpepimut-S (GPS)
Dec 20, 2018: Cue Biopharma and LG Chem Life Sciences Announce WT1 as the Next Immuno-STAT Target in Oncology
Nov 28, 2018: SELLAS Life Sciences announces expedited development path for Galinpepimut-S (GPS) in acute myeloid leukemia (AML) following feedback from FDA
Sep 13, 2018: SELLAS Receives Orphan Medicil Product Desigtion Approval by the Committee for Orphan Medicil Products of the European Medicines Agency for Galinpepimut-S for the Treatment of Patients with Multiple Myeloma
Aug 20, 2018: Inovio doses first patient in Phase l/lla of INO-5401 and atezolizumab
Jul 20, 2018: SELLAS Receives Fast Track Desigtion from FDA for Galinpepimut-S for the Treatment of Patients with Multiple Myeloma
Jun 21, 2018: Inovio Announces Treatment of First Patient in Immuno-Oncology Study for Glioblastoma (GBM) with INO-5401 in Combition with Regeneron’s PD-1 Inhibitor
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019


List of Tables


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Cue Biopharma Inc, H2 2019
Pipeline by Inovio Pharmaceuticals Inc, H2 2019
Pipeline by Scancell Holdings Plc, H2 2019
Pipeline by SELLAS Life Sciences Group Inc, H2 2019
Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2019
Pipeline by tella Inc, H2 2019
Pipeline by Vaximm AG, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019